Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Micafungin: a new echinocandin.

P H Chandrasekar1, J D Sobel

  • 1Division of Infectious Diseases, Wayne State University School of Medicine/Detroit Medical Center, Detroit, Michigan, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|April 1, 2006
PubMed
Summary

Micafungin, an echinocandin antifungal, shows broad in vitro activity against Candida and Aspergillus species, similar to caspofungin. Clinical data are emerging for its use in esophageal candidiasis and neutropenic prophylaxis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated microscopy and pH test for diagnosis of vaginitis - the end of empiricism?

NPJ digital medicine·2023
Same author

Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center.

Antimicrobial agents and chemotherapy·2023
Same author

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Recurrent bacterial vaginosis, relapse or reinfection: the role of sexual transmission.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure.

Current infectious disease reports·2019
Same author

Candida parapsilosis Vaginal Infection-a New Site of Azole Drug Resistance.

Current infectious disease reports·2018

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Micafungin is a novel echinocandin antifungal agent.
  • It targets 1,3-beta-D-glucan synthase, crucial for fungal cell wall integrity.
  • It is the second echinocandin approved for clinical use.

Purpose of the Study:

  • To review the in vitro activity, clinical role, and safety of micafungin.
  • To compare micafungin with caspofungin, another echinocandin.
  • To discuss factors influencing micafungin's clinical adoption.

Main Methods:

  • Review of in vitro susceptibility data.
  • Analysis of available clinical trial data for efficacy and safety.
  • Pharmacokinetic and pharmacodynamic assessment.

Related Experiment Videos

  • Comparison with existing echinocandin agents.

    • Main Results:

    • Micafungin exhibits broad in vitro activity against Candida and Aspergillus species, comparable or superior to caspofungin.
    • Clinical data are limited but suggest similar roles to caspofungin, including treatment of esophageal candidiasis and prophylaxis in neutropenia.
    • Pharmacokinetic, pharmacodynamic, and safety profiles are similar but not identical to other echinocandins.

    Conclusions:

    • Micafungin is a potent antifungal with a spectrum of activity similar to caspofungin.
    • Further clinical data are needed to fully elucidate its therapeutic role and advantages.
    • Cost and resistance development may significantly impact micafungin's widespread clinical use.